Bionovis has a technical and commercial collaboration agreements with two of the world’s largest biotechnology companies, Janssen and Merck. These unique partnerships involve the transfer of the entire production technology, including the master cell bank, for various highly complex biological products to Bionovis and its public partners, Bio-Manguinhos / Fiocruz and Instituto Vital Brazil.
Bionovis also has a commitment with the Ministry of Health as part of the Partnerships for Productive Development (PDPs), with the aim to increase access to highly effective medicines by supplying the Public Health System with eight locally produced Biopharmaceuticals.
Merck is a leader in innovative, superior quality products in the pharmaceutical and chemical sectors. Through its four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck has generated total revenues of € 11.1 billion in 2013. About 39,000 Merck employees are working in 66 countries in order to improve the quality of life of patients, promote the success of customers and help addressing global healthcare challenges. Merck is the oldest pharmaceutical and chemical company in the world and since 1668 is synonymous with innovation, business success and responsible entrepreneurship. The founding family remains the majority shareholder holding 70% of the company. Merck, Darmstadt, Germany, owns the rights for the global name and brand Merck with the exceptions of Canada and the United States, where the company is known as EMD.
he Institute of Technology in Immunobiology (Bio-Manguinhos) is the unit of the Oswaldo Cruz Foundation (Fiocruz) responsible for technology, development and production of vaccines, reagents and biopharmaceuticals targeted to meet priority demands of national public health. The Vaccines Technological Complex (CTV) of the Institute, one of the largest and most modern production centers in Latin America, located on the campus of Fiocruz, ensures self-sufficiency in essential vaccines for the routine immunization schedule of the Ministry of Health (MOH).
FINEP is a public company under the MCTI (Ministry of Science, Technology and Innovation) established on 24 July 1967. Its purpose is to function in the whole chain of innovation, focusing on strategic and structural actions affecting the sustainable development of Brazil. The ability to finance the entire Science, Technology and Innovation system, combining refundable and non-refundable resources, as well as other instruments, enables FINEP to induce innovation activities, essential for improving the competitiveness of the business sector.
The National Bank for Economic and Social Development (BNDES), a federal public company, is today the main long-term financing instrument of investments in all branches of the economy: agriculture, industry, trade, services and infrastructure, providing special conditions for micro, small and medium enterprises. The promotion of exports and the strengthening of the capital markets remain key strategic actions. Present in all sectors, BNDES promotes increased competitiveness and the strengthening of the national economy, supports the social and cultural advancement and contributes to increase access of all citizens to a better life, with more education, health, employment and citizenship.
Would you like to be our partner? Contact us and find out how to participate in our innovative projects.